APIRx-1803

**APIRx-1803** is an ultrapure cannabigerol (CBG) pharmaceutical candidate developed by APIRx Pharmaceuticals, featuring a patented high-purity cannabinoid active pharmaceutical ingredient (API). CBG is a non-psychoactive phytocannabinoid from cannabis that acts as an agonist at CB1 and CB2 receptors, with potential anti-inflammatory, antimicrobial, neuroprotective, and analgesic effects. It targets multiple indications including glaucoma, conjunctivitis, atopic dermatitis, vitiligo, psoriasis, and osteonecrosis of the jaw through sustained-release technologies like medicated chewing gum tablets (MCGTs) for improved bioavailability via oral mucosa absorption, bypassing first-pass metabolism. The project is listed as "Developed" with granted patents, part of APIRx's cannabinoid pipeline now under Incannex Healthcare following acquisition.